- Our LinkedIn Page
- Our Twitter Feed
- Our Facebook Page
- Newsletter Subscribe to our e-newsletter. Current Issue
- Our Flickr Feed
- Our YouTube Feed
Tags
drug development Health Care Biotechnology Industry biotechnology Investment Partnering Industry Analysis 2012 BIO International Convention BIOTECH PUBLIC BIOTECH - Stats One-on-One's biotech industry FDA PUBLIC BIOTECH - Stock performance IPO Events economic development economy BIO International Convention patentAuthors
- Abigail Hirsch
- Alan Eisenberg
- BIOtechNOW Editor
- Bruce Dale
- Celia Economides
- Colleen Lerro
- David Thomas, CFA
- George Goodno
- George MacDougall
- Jason Corum
- Jeff Joseph
- Jim Greenwood
- Karen Batra
- Kelly Cappio
- Lila Feisee
- Matt Carr
- Nathan Schock
- Paul Winters
- Paulina Ibarra
- Robbi Lycett
- Roy Zwahlen
- Sarah Sneeringer
- Sondra Behan
- Stephanie Fischer
- Stephen Marmaras
- Tracy Cooley
Corporate
- Biofuels & Climate Change
- Biotech Blog
- Business & Investments
- Business of Biotech
- Capital Business
- Corporate
- Environmental & Industrial
- Events
- Farmer Gene
- FierceBiotech
- Food & Agriculture
- Genome Alberta
- Health
- Inside BIO Industry Analysis
- IP Watchdog
- Life Science Leader
- One-on-One Partnering
- Patent Baristas
- Patent Docs
- Patently BIOtech
- PharmTech Talk
- Public Policy
- Snapshot
- Trade Secrets Blog
Latest From Biotech Now
Mayo v. Prometheus: Thought Leaders Express Concern and Evaluate the Impact
The Mayo v. Prometheus event hosted at George Washington School of Law with the Biotechnology Industry Organization created an opportunity for a panel of thought leaders to distill meaning from the case, the impact on personalized medicine, and possible solutions to the Court created problem.* Is the decision a game-changer? Judge Paul R. Michel, former Chief Judge of the Court of Appeals for the Federal Circuit handling patent cases, concluded that the Mayo v. Prometheus Read More >
Greenwood Tells House Ag Subcommittee: Farm Bill Energy Programs Are Working
The Subcommittee on Conservation, Energy, and Forestry held its final hearing today on the 2012 Farm Bill. Testimony focused on Formulation of the 2012 Farm Bill: Energy and Forestry Programs. BIO’s President & CEO Jim Greenwood joined the panel testifying about Farm Bill energy programs along with Ryan Stroschein, Agriculture Energy Coalition; Steve Reinford, Reinford Farms Inc.; Jerry Taylor, MFA Oil; and Gary Haer, National Biodiesel Board. “Farm Bill energy programs are working and BIO Read More >
May is Celiac Disease Awareness Month
Celiac disease is one of the most common autoimmune conditions in the U.S. but frequently goes undiagnosed. The cause is currently unknown and it can develop at any point in life. People who have a relative with the disease are more likely to develop it, and women are more likely than men to have it. When people with celiac disease eat food with gluten, their immune system reacts by damaging areas of the lining of Read More >
Why Biotech Food Labeling Is Met with Resistance
In recent weeks, there’s been a lot of new discussion around the biotech labeling debate. On May 10, the International Food Information Council (IFIC) released its latest “Consumer Perceptions of Food Technology” survey, which showed that very few Americans cite biotechnology as an information need on food labels. Earlier this month, the California Right to Know initiative announced at various rallies held around the state that it had collected the prerequisite number of signatures to Read More >
Announcing the Buzz of BIO Winner for Pipelines of Promise!
We’re very pleased to announce the Buzz of BIO Winner for the 2012 contest of the BIO International Convention. You voted for your favorites, and it was a tight, interesting race! As such, we’re pleased to introduce you to our winner for the Pipelines of Promise category. Deuteria Pharmaceuticals, Inc,. who focuses on improving the product profile of approved drugs through ‘chiral switching’, won the Pipelines of Promise category. From Dr. Sheila DeWitt, the company’s Read More >
